Drug profile

The FDA adverse-event record for Distemper-Adeno-Parvo-4Way Lepto

29 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference Distemper-Adeno-Parvo-4Way Lepto. See the species affected, top reactions, and outcomes below.

29
adverse-event reports
6.9%
death-coded share
Dog
most-reported species
16
Vomiting - top reaction
Verify with FDA CVM →
Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
29
Total Reports
2
Deaths Reported
6.9%
Death Rate

Active Ingredients

Distemper-Adeno-Parvo-4Way Lepto

Administration Routes

SubcutaneousUnknown

Species Affected

Dog 29

Most Affected Breeds

Chihuahua 4
Boxer (German Boxer) 3
Retriever - Golden 2
Retriever - Labrador 2
Dachshund - Standard Smooth-haired 1
Terrier - Bull - American Pit 1
Komondor 1
Spaniel (unspecified) 1
Shih Tzu 1
Terrier - Jack Russell 1

Most Reported Reactions

Vomiting 16
Anaphylaxis 11
Facial swelling (see also 'Skin') 6
Hives (see also 'Skin') 5
Lethargy (see also Central nervous system depression in 'Neurological') 5
Diarrhoea 4
Lateral recumbency 4
Laboured breathing 3
Bloody diarrhoea 3
Anorexia 3
Vocalisation 2
Collapse NOS (see also 'Cardio-vascular' and 'Neurological disorders') 2

Outcome Breakdown

Ongoing
17 (58.6%)
Recovered/Normal
10 (34.5%)
Died
1 (3.4%)
Euthanized
1 (3.4%)

Distemper-Adeno-Parvo-4Way Lepto Adverse Event Insights

29 reports name Distemper-Adeno-Parvo-4Way Lepto; 2 recorded a death outcome (6.9% of reported events, not a population-level mortality rate). Active ingredient: Distemper-Adeno-Parvo-4Way Lepto. Administration routes: Subcutaneous, Unknown.

By species: Dog (29 reports). By breed: Chihuahua (4), Boxer (German Boxer) (3), Retriever - Golden (2).

Leading clinical signs: Vomiting (16), Anaphylaxis (11), Facial swelling (see also 'Skin') (6), Hives (see also 'Skin') (5). Outcome, 29 coded reports: Ongoing leads at 58.6%.

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

Every figure on PlainBreed is rendered directly from FDA openFDA adverse event data, no number is typed in by an editor. This page draws directly on FDA openFDA data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.